Aigen Investment Management LP Purchases Shares of 4,669 IQVIA Holdings Inc. $IQV

Aigen Investment Management LP acquired a new position in IQVIA Holdings Inc. (NYSE:IQV) in the 4th quarter, HoldingsChannel.com reports. The firm acquired 4,669 shares of the medical research company’s stock, valued at approximately $1,052,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Brighton Jones LLC boosted its holdings in shares of IQVIA by 244.4% in the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after acquiring an additional 2,537 shares during the last quarter. Empowered Funds LLC raised its holdings in shares of IQVIA by 102.1% during the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after purchasing an additional 4,915 shares during the last quarter. Sivia Capital Partners LLC acquired a new position in IQVIA during the second quarter valued at $514,000. First Trust Advisors LP lifted its position in IQVIA by 14.8% during the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock valued at $14,501,000 after purchasing an additional 11,845 shares during the period. Finally, NewEdge Advisors LLC boosted its holdings in IQVIA by 5.4% in the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock valued at $3,582,000 after purchasing an additional 1,155 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Down 0.2%

Shares of NYSE IQV opened at $181.10 on Monday. The firm has a market cap of $30.23 billion, a price-to-earnings ratio of 22.44, a price-to-earnings-growth ratio of 1.56 and a beta of 1.21. The company’s 50-day simple moving average is $173.56 and its 200-day simple moving average is $193.44. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA Holdings Inc. has a 52-week low of $153.01 and a 52-week high of $247.04.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. During the same quarter in the prior year, the firm earned $2.70 EPS. The company’s revenue for the quarter was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities analysts predict that IQVIA Holdings Inc. will post 11.6 EPS for the current fiscal year.

IQVIA declared that its Board of Directors has authorized a share repurchase plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of analysts have recently commented on IQV shares. Barclays upgraded IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 target price on the stock in a research note on Friday, March 6th. Royal Bank Of Canada initiated coverage on IQVIA in a report on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price target for the company. TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and upped their price objective for the stock from $174.00 to $213.00 in a research report on Monday, March 9th. HSBC set a $210.00 target price on shares of IQVIA in a report on Wednesday, June 3rd. Finally, Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a report on Sunday. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $224.13.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.